Richmond Pharmacology is pleased to confirm our attendance at the EASL Congress 2025 in Amsterdam, one of the leading global events dedicated to liver research and hepatology, hosted by the European Association for the Study of the Liver.

This year’s congress will bring together experts from across the world to share the latest developments in liver disease research, clinical innovation, and therapeutic advances.

Representing Richmond Pharmacology:

  • Dr Jörg Täubel, Chief Executive Officer

Our team looks forward to engaging with clinical leaders, researchers, and industry partners to explore opportunities in:

  • Early-phase hepatology research
  • Rare and metabolic liver disease trials
  • Regulatory strategy and scientific advice

If you are attending EASL Congress and would like to learn how Richmond Pharmacology can support your liver-focused clinical development, we welcome you to connect with us during the event.

For meeting requests or collaboration enquiries:
info@richmondpharmacology.com

Learn more about the event:

Latest news

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
Read more

Upcoming Event

ESC Congress 2026

28 - 31 August 2026
Richmond Pharmacology is pleased to attend the ESC Congress 2026 in Munich, Germany, on 28 - 31 August 2026.
View event